Neurodegenerative Diseases DNA Methylation Biomarker DiscoveryInquiry
Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD), are often associated with the onset of aging. Most of the current biomarker assays for neurodegenerative diseases are based on expensive and invasive techniques, then the search for biomarkers that can be detected by cost-effective, highly comfortable techniques is of great application.
DNA methylation is one of the more widely studied epigenetic biomarkers. There is also a growing research effort to identify and validate DNA methylation changes in aging and age-related neurodegenerative diseases, thus DNA methylation may have great potential as an early diagnostic biomarker for neurodegenerative diseases. CD BioSciences can provide DNA methylation biomarker discovery services for neurodegenerative diseases.
Our Discovery Strategies
We primarily use candidate gene methylation analysis and genome-wide DNA methylation analysis strategies to discover biomarkers for neurodegenerative diseases.
Advanced Technology Platform
We have a comprehensive and proven DNA methylation analysis technology, as well as unique DNA methylation age clock, telomere age clock, and other age clock technologies that combine to form a complete technology platform for aging longevity and other age-related studies.
Trusted Professional Team
Our team has researchers specializing in epigenetics, related disease areas, which have cutting-edge domain knowledge and extensive research experience. They can select the best DNA methylation biomarker strategy according to the customer's research field and application direction.
- It can be applied to combine DNA methylation testing with existing diagnostic tools/biomarkers for neurodegenerative diseases to aid in rapid execution of the early detection, diagnosis and therapy formulation.
- It can be applied to combine DNA methylation testing with genetic screening to enhance the identification of individuals suffering from hereditary neurodegenerative diseases.
- The discovery of DNA methylation at specific genomic loci can be applied to the development of personalized therapies for specific individuals.
CD BioSciences specializes in research and technology supply based on DNA methylation analysis assays, mainly for biotechnology, healthcare and other industries related to DNA methylation analysis. We are committed to providing customized services to help clients overcome technical difficulties in research and accelerate the discovery and application of DNA methylation biomarkers.
If you have any related ideas, please feel free to contact us and we help you to realize your DNA methylation biomarker discovery project.
- Jakubowski, J L and Labrie, V. Epigenetic Biomarkers for Parkinson's Disease: From Diagnostics to Therapeutics. Journal of Parkinson's Disease, 2017:1 – 12.
Our services are for research use only and not for any clinical use.
We are a comprehensive technology platform company integrating aging DNA methylation, telomere, transcriptome, proteome, and metabolome research.